Related references
Note: Only part of the references are listed.Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view
Frederick W. Thielen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
Josep Maria Ribera Santasusana et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2020)
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Matthew Walton et al.
PHARMACOECONOMICS (2019)
A Systematic Review and Meta-analysis of Childhood Health Utilities
Joseph Kwon et al.
MEDICAL DECISION MAKING (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Systematic review of health state utility values for acute myeloid leukemia
Anna Forsythe et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)
Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial
Michaela Kuhlen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
Robert Hettle et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
Audrey Bonaventure et al.
LANCET HAEMATOLOGY (2017)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Pharmacoeconomic Evaluation Process in Ireland
Laura McCullagh et al.
PHARMACOECONOMICS (2016)
Long term cause specific mortality among 34489 five year survivors of childhood cancer in Great Britain: population based cohort study
Miranda M. Fidler et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Long term cause specific mortality among 34489 five year survivors of childhood cancer in Great Britain: population based cohort study
Miranda M. Fidler et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample: A Nonparametric Regression Approach
Mark Strong et al.
MEDICAL DECISION MAKING (2014)
How I treat relapsed childhood acute lymphoblastic leukemia
Franco Locatelli et al.
BLOOD (2012)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Richard H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Populating an Economic Model with Health State Utility Values: Moving toward Better Practice
Roberta Ara et al.
VALUE IN HEALTH (2010)
Calculating partial expected value of perfect information via Monte Carlo sampling algorithms
Alan Brennan et al.
MEDICAL DECISION MAKING (2007)
Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada
Amy C. MacArthur et al.
PEDIATRIC BLOOD & CANCER (2007)
Health state utilities for metastatic breast cancer
A. Lloyd et al.
BRITISH JOURNAL OF CANCER (2006)
Health-related quality of life of pediatric patients receiving allogeneic stem cell or bone marrow transplantation: results of a longitudinal, multi-center study
R. Felder-Puig et al.
BONE MARROW TRANSPLANTATION (2006)
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
S Bhatia et al.
BLOOD (2005)
Discounting for health effects in cost-benefit and cost-effectiveness analysis
H Gravelle et al.
HEALTH ECONOMICS (2001)
Share Paper
